United Kingdom (UK)
Recombinant monoclonal antibody to Envelope glycoprotein H and L. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody rec-RC-IgG.
UniProt Accession Number of Target Protein: Q775J3; Q9J3N1
Alternative Name(s) of Target: gHgL; gH; gL; envelope glycoprotein H; envelope glycoprotein L; Varicella zoster virus; VZV; human herpesvirus 3; HHV-3; HHV3; Human alpha herpesvirus 3; Chickenpox; IgG-RC
Immunogen: The original antibody was isolated from circulating blood plasmablast of a 59-year-old VZV-seropositive man recently immunized with zoster vaccine Zostavax.
Specificity: This antibody targets the domain IV region of envelope glycoprotein B of the Varicella zoster virus (VZV) also known as the human herpesvirus 3 (HHV-3, HHV3) or Human alpha herpesvirus 3. This DNA virus from the herpes virus group can infect humans causing chickenpox in children and shingles (herpes zoster) in adults. Varicella is characterized by a maculopapular, vesicular rash that can be pruritic and evolves into dried crusts (scabs) over a 3- to 7-day period. Chicken pox is considered contagious beginning 1-2 days before rash onset until all lesions have crusted (scabbed).
Application Notes: This antibody was used for the immunohistochemical staining of fixed and unfixed VZV-infected and control human lung fibroblast cells. This antibody was also reported to neutralize VZV infection in a plaque reduction assay. The concentration of IgG that produced 50% plaque reduction was 0.6 μg/ml. This antibody was also used for the immunoprecipitation of VZV-infected cells (PMID: 23077312).
Antibody first published in:
Birlea et al. Human Anti-Varicella-Zoster Virus (VZV) Recombinant Monoclonal Antibody Produced after Zostavax Immunization Recognizes the gH/gL Complex and Neutralizes VZV Infection. J Virol. 2013 Jan; 87(1): 415–421. PMID:23077312
Note on publication:
This paper describes the generation of a recombinant monoclonal antibody from the circulating blood plasmablast of a VZV-seropositive man immunized with zoster vaccine Zostavax.